In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Adds to Pipeline with Organon Acquisition

Executive Summary

In a bold move it says will bolster its late-stage pipeline and provide necessary scale in sales and biologics manufacturing, Schering-Plough Corp. is acquiring the CNS and women's health specialist Organon BioSciences from Dutch conglomerate Akzo Nobel for $14.4 billion. For the acquisition to be a success, SP will have to find value where others have not--specifically in Organon's Phase III schizophrenia treatment asenapine, which was handed back to the company by Pfizer after disappoinging clinical results.
Advertisement

Related Content

Deal Statistics Quarterly, Q1 2007
Deal Statistics Quarterly, Q1 2007
European Consolidation: Serious Competition for Big Pharma?
European Consolidation: Serious Competition for Big Pharma?
Organon Reboots with Biotech
Organon Reboots with Biotech
Organon Kicks Off Partnering Strategy with Pfizer Deal
Schering-Plough: What Went Wrong, What to Do
Schering-Plough: What Went Wrong, What to Do
Akzo Pharma's Fall and Rise

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002931

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel